-
First oral CGRP-subject antagonist migraine drug! El Jian ubrogepant will submit a listing application in early 2019:
Time of Update: 2021-02-14
Allergan recently announced that it has completed two clinical studies of ubrogepant for acute migraine treatment and has obtained positive safety and tolerance data. first study (UBR-MD-04) assessed the long-term safety and tolerance
-
Neurology: Angiotensin II stimulates antihypertensive drugs, or helps prevent dementia
Time of Update: 2021-01-17
other antihypertensive drugs, the subcatfacies most associated with reducing the risk of dementia are angiotensin blockers, certain calcium channel blockers, and diuretics.
-
Identification of Adipokine Receptor Agonists and Turning Them to Antagonists
Time of Update: 2020-12-17
A recent discovery and design process for leptin and adiponectin receptorresponse modifier peptides can be generalized to a series of transmembrane receptor ligands.
-
New drug for uterine fibroids! Best-in-class GnRH subject antagonist linzagolix EU applied for listing
Time of Update: 2020-12-14
results showed that both trials had successfully reached the main endpoint: A significant statistical and clinical reduction in HMB in all dose groups compared to placebos.
-
Chemokine Receptor Antagonist Development
Time of Update: 2020-12-08
This chapter describes assays that focus on the characterization of compounds identified in high-�throughput screening campaigns,and the subsequent medicinal chemistry programs. They cover methods to determine potency in buffer
-
New migraine drug! AbbVie oral CGRP receptor antagonist atogepant prevention migraine Phase III clinical success!
Time of Update: 2020-08-06
data showed that all atogepant dose groups reached the primary endpoint and that the average number of migraine days per month was statistically significantly reduced compared to placebos.
-
Adenosine inhibitors immuno-micro-environment-regulating drugs for tumors (I) : A2aR antagonists.
Time of Update: 2020-08-01
AZD4635 related clinical trials 3 CPI-444 CPI-444 developed by Corvus and Roche, currently nSCLC indications into Phase II clinical indications have NSCLC, its clinical use strategy includes single drug, with PD-L1 mono-resistance, with CD73 mono-resistance, and CD38 mono-resistance combination.
-
New anti-transplant drugs! IL-2 Receptor Targeting Immunotherapy Leukotac is on the market
Time of Update: 2020-07-31
application (BLA) for the treatment of patients with SR-aGvin disease in the class II-IV steroid refractive acute transplantation (SR-aGv). the BLA will be reviewed through the FDA Real-Time Oncology Review Pilot Program (RTOR), an initiative
-
Oral GnRH receptor antagonists for endometriosis Phase 2 Clinical End.
Time of Update: 2020-07-20
On June 23, Myovant Sciences published the top-line results of the SPIRIT 1 study, the second phase III study to evaluate the relugolix combination therapy (relugolix 40mg plus estradiol 1.0mg plus acetate ketone 0.5mg) to treat pain associated
-
A new drug for specific dermatitis (AD) itching! New anti-inflammatory drug: IL-31 receptor
Time of Update: 2020-07-17
the percentage of patients with a quality of life index (DLQI) score of 4, 40 percent in the nemolizumab group and 22 percent in the placebo group.
-
Gupon: Angiotensin conversion enzyme inhibitors/angiotensin receptor blockers associated with lower risk of colorectal cancer
Time of Update: 2020-07-14
The risk ratio for colorectal cancer, adjusted by ACE inhibitor/angiotensin receptor blockers, was derived by matching score regression on 23 covariates, including patient factors, simultaneous medication, and endoscopic center performance.
-
New drugs for insomnia! The eludant of ego receptor seroinion, Dayvigo (lemborexant), is on the market in Hong Kong, China!
Time of Update: 2020-07-14
, July 09, 2020 / bio-valley smh.com.au/Eisai has announced that a new drug application for its insomnia drug Dayvigo (lemborexant) has been accepted by the Hong Kong Special Administrative Region Of China Health Department
-
A new HIV-1 receptor may become a target for the development of new AIDS drugs
Time of Update: 2020-07-04
Integrator alpha4 beta7 is a normal component of human cells, located in the mucous membrane of the digestive tract, and is the peripheral T-cell nesting receptor.
-
EU approves type 2 diabetes drug GLP-1 receptor agonist Rybelsus
Time of Update: 2020-06-25
Novo Nordisk today announced that the European Medicines Agency (EMA) has approved the sale of the company's oral GLP-1 receptor agonisant Rybelsus (semaglutide) to help control blood sugar in people with type 2 diabetes.
-
Phase 3 clinical studies have confirmed that the gonadotropin-releasing hormone (GnRH) receptor
Time of Update: 2020-06-22
in spirit 2 results analysis, 75.2% of women who received relugolix combination therapy achieved clinically meaningful improvements in menstruation, compared with 30.4% in the placebo group (p 0.0001).
-
New drugs for insomnia! The eludant of ego receptor serombia is available in the United States!
Time of Update: 2020-06-17
, June 04, 2020 / PRNewswire/ -- Eisai, a Japanese pharmaceutical company, recently announced the launch of the new insomnia drug Dayvigo (lerexmboant) CIV in the U.S. market, which comes in two sizes (5mg and 10mg tablets
-
Adenosine inhibitors immuno-micro-environmental regulatory drugs for tumors (I) : A2aR antagonists
Time of Update: 2020-06-15
, AZD4635 was developed by AstraZeneca and currently has prostate cancer and NSCLC and other indications into Phase II clinical, its clinical use strategy includes single drug, with PD-L1 monoantiphoresis, and CD73 monotonica.
-
FDA accepts new drug application from androgen receptor (AR) antagonist darolutamide
Time of Update: 2020-06-09
FDA ( accepted the company's application for new drug ( (NDA) for the androgen receptor (AR) antagonist darolutamide for the treatment of non-metastatic resistance prostate cancer (CRNM).
-
Her reached primary and secondary endpoints in the 3rd phase of the study of GnRH receptor antagonist relugolix
Time of Update: 2020-06-07
today, Myovant Sciences company ( announced that it has reached the primary and all critical secondary endpoints in the Phase 3 study HERO for the treatment of patients with advanced prostate cancer.
-
5th approval! Lilly's anti-inflammatory drug Taltz is approved by the U.S. FDA: the first IL-17A
Time of Update: 2020-06-05
June 02, 2020 / Biovalley BIOON/ -- Lilly recently announced that the U.S. Food and Drug Administration ( FDA ) has approved taltz ( 80mg/mL injection) a new indication for the treatment
